Evidence map›Paper›PMID 35485272›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022

Public health considerations for transitioning beyond the acute phase of the COVID-19 pandemic in the EU/EEA.

Jonathan E Suk, Anastasia Pharris, Julien Beauté, Edoardo Colzani, Howard Needham, John Kinsman, Rene Niehus, Rok Grah, Ajibola Omokanye, Diamantis Plachouras and 7 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jonathan E SukEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Anastasia PharrisEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Julien BeautéEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Edoardo ColzaniEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Howard NeedhamEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
John KinsmanEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Rene NiehusEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Rok GrahEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Ajibola OmokanyeEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Diamantis PlachourasEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Agoritsa BakaEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Bastian PrasseEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Frank SandmannEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Ettore SeveriEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Erik AlmEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Emma WiltshireEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Bruno CiancioEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many countries, including some within the EU/EEA, are in the process of transitioning from the acute pandemic phase. During this transition, it is crucial that countries' strategies and activities remain guided by clear COVID-19 control objectives, which increasingly will focus on preventing and managing severe outcomes. Therefore, attention must be given to the groups that are particularly vulnerable to severe outcomes of SARS-CoV-2 infection, including individuals in congregate and healthcare settings. In this phase of pandemic management, a strong focus must remain on transitioning testing approaches and systems for targeted surveillance of COVID-19, capitalising on and strengthening existing systems for respiratory virus surveillance. Furthermore, it will be crucial to focus on lessons learned from the pandemic to enhance preparedness and to enact robust systems for the preparedness, detection, rapid investigation and assessment of new and emerging SARS-CoV-2 variants. Filling existing knowledge gaps, including behavioural insights, can help guide the response to future resurgences of SARS-CoV-2 and/or the emergence of other pandemics. Finally, 'vaccine agility' will be needed to respond to changes in people's behaviours, changes in the virus, and changes in population immunity, all the while addressing issues of global health equity.

Indexed as

COVID-19HumansPandemicsPublic HealthSARS-CoV-2COVID-19epidemiologyglobal health governancepandemic preparednessSARS-CoV-2

Identifiers

PMID35485272
PMCPMC9052765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.